TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
- Groundbreaking thymus-rejuvenating biologics are designed to restore immune function and promote lasting immune health throughout all stages of life
Basel, Switzerland, January 8, 2026 – TECregen, a biotechnology company pioneering thymus regeneration, today announced the successful completion of a CHF 10 million (∼EUR 10.7 million / USD 12.6 million) seed financing round. The financing was led by the Boehringer Ingelheim Venture Fund (BIVF), with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. The investment will accelerate development of TECregen’s groundbreaking thymopoietic biologics, designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen overall immune resilience.
